Introduction of Non-Invasive Body Slimming and Contouring Treatments
|
 |
|
|
 |
| At LyVin Clinic, we understand that finding safe and effective body slimming options can be confusing. That's why at LyVin Clinic, we use only FDA-approved machines for our non-invasive procedures. FDA approval means the machines have been thoroughly tested for safety and quality. We prioritize your safety and want to ensure you get the best results without any complications. By using FDA-approved machines, we can provide you with the highest level of care and satisfaction. Trust us with your aesthetic needs and experience the difference. |
 |
| Make an Appointment |
|
| |
|
|
|
|
| |
|
|
| |
Experience The BEST
|
 |
| Here are some reasons why our non-invasive procedures are popular at our clinic: |
 |
| Firstly, Safety is our top priority. We believe in using only authentic devices to minimize complications and deliver optimal results. Besides, Our doctors are certified and experienced. They conduct a comprehensive assessment and discuss the treatment plan with the patient before any procedure. Our client-centric approach ensures the best possible outcome. |
 |
| We offer a full range of body slimming and sculpting treatments, including visceral fat, subcutaneous fat, muscle, overweight, stretch marks, cellulite, and loose skin. Furthermore, we understand the importance of post-treatment care. Our comprehensive plan is designed to get our patients back to their daily activities as soon as possible. |
 |
| At our clinic, we prioritize your safety and satisfaction. Contact us today to schedule an appointment and experience the difference for yourself. |
|
|
|
|
| |
 |
Monday to Saturday
10:00am - 6:30pm
Closed on every Sunday
& Selected Public Holiday |
|
| |
|
|
|
|
|
|
| |
|
|
| |
Mounjaro
|
| |
|
|
|
|
| |
|
|
| |
| |
| |
| Mounjaro vs Semaglutide (Wegovy®) |
 |
| Feature |
Mounjaro (Tirzepatide) |
Semaglutide (Wegovy®) |
| Receptor |
Dual GIP + GLP-1 |
GLP-1 only |
| Average Weight Loss (72 wks) |
–22.5% (15 mg) |
~–15% |
| Visceral Fat Reduction |
Up to 45% |
Lower effect compared to tirzepatide |
| Waist Circumference Reduction |
~–20 cm |
~–13 cm |
| FDA Approval |
Approved for diabetes (Mounjaro) + obesity |
Approved for obesity (Wegovy) |
|
| The 7.5% Difference: The additional weight loss with Mounjaro can be the difference between simply improving health risks and truly transforming them. Losing >20% of body weight is a game-changer. |
| |
| Targeting the Root Cause: Visceral fat is metabolically active and drives inflammation and insulin resistance. Mounjaro's potent reduction of this fat directly attacks the core of metabolic disease. |
|
|
|
|